Palvella Therapeutics, Inc.
PVLANASDAQHealthcare● Active
$105.25
$-3.42(-3.15%)
Market Cap$1.2B
P/E Ratio—
52W High$151.18
52W Low$20.2
Palvella Therapeutics, Inc. (PVLA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PVLA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.20
Est. -$0.90 · -33.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
PVLA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$1.16 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.90 | -$1.20 | -33.3% | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.91 | -$1.08 | -18.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 11, 2025 | -$0.85 | -$1.03 | -21.2% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.78 | -$0.86 | -10.3% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$3.40 | -$0.74 | +78.2% | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.39 | $4.00 | +1125.6% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.55 | -$2.19 | -301.8% | — | $0.00B | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$1.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.20
EPS Est.
-$0.90
EPS Surpr.
-33.3%
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$1.08
EPS Est.
-$0.91
EPS Surpr.
-18.5%
Revenue
—
Q4 FY2025
Nov 11, 2025Miss
EPS Actual
-$1.03
EPS Est.
-$0.85
EPS Surpr.
-21.2%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.86
EPS Est.
-$0.78
EPS Surpr.
-10.3%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.74
EPS Est.
-$3.40
EPS Surpr.
+78.2%
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
$4.00
EPS Est.
-$0.39
EPS Surpr.
+1125.6%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$2.19
EPS Est.
-$0.55
EPS Surpr.
-301.8%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.75 | $-1.75 | $-1.75 | 6 |
| Q3 FY2027 | $-2.04 | $-2.04 | $-2.04 | 3 |
| Q2 FY2027 | $-1.88 | $-1.88 | $-1.88 | 5 |
| Q1 FY2027 | $-1.79 | $-1.79 | $-1.79 | 3 |
| Q4 FY2026 | $-1.76 | $-1.76 | $-1.76 | 6 |
| Q3 FY2026 | $-1.82 | $-1.46 | $-1.13 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -33.3% | $130.17 | $113.26 | -12.99% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -18.5% | $110.66 | $124.65 | +12.64% |
| ▼ Q4 FY2025 | Nov 11, 2025 | -21.2% | $80.29 | $77.85 | -3.04% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -10.3% | $44.64 | $46.10 | +3.27% |
| ▲ Q2 FY2025 | May 15, 2025 | +78.2% | $21.70 | $21.61 | -0.41% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +1125.6% | $28.10 | $27.99 | -0.39% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -301.8% | No price data | $17.00 | — |
| ▼ Q3 FY2024 | Aug 14, 2024 | -15.0% | No price data | $17.00 | — |
Q2 FY2026-12.99%
Report Date
May 7, 2026
EPS Beat/Miss
-33.3%
Price Before
$130.17
Price After
$113.26
Q1 FY2026+12.64%
Report Date
Mar 31, 2026
EPS Beat/Miss
-18.5%
Price Before
$110.66
Price After
$124.65
Q4 FY2025-3.04%
Report Date
Nov 11, 2025
EPS Beat/Miss
-21.2%
Price Before
$80.29
Price After
$77.85
Q3 FY2025+3.27%
Report Date
Aug 14, 2025
EPS Beat/Miss
-10.3%
Price Before
$44.64
Price After
$46.10
Q2 FY2025-0.41%
Report Date
May 15, 2025
EPS Beat/Miss
+78.2%
Price Before
$21.70
Price After
$21.61
Q1 FY2025-0.39%
Report Date
Mar 31, 2025
EPS Beat/Miss
+1125.6%
Price Before
$28.10
Price After
$27.99
Q4 FY2024—
Report Date
Nov 13, 2024
EPS Beat/Miss
-301.8%
Price Before
—
Price After
$17.00
Q3 FY2024—
Report Date
Aug 14, 2024
EPS Beat/Miss
-15.0%
Price Before
—
Price After
$17.00
Avg Beat Reaction-0.40%
Avg Miss Reaction-0.03%
Beat Rate2 / 8 quarters
Largest Move-12.99% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PVLA ends December
Palvella Therapeutics, Inc. (PVLA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.20 — missing the analyst consensus of $-0.90 by -33.3%. The next PVLA earnings date is expected around September 1, 2026.
Each quarter, investors track PVLA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PVLA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PVLA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PVLA earnings · 5 questionsPalvella Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. PVLA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PVLA historically reports after market close (AMC).
PVLA earnings datewhen is PVLA earningsPVLA next earnings datewhen does PVLA report earningsPVLA earnings calendar
▸ Source: FMP · Palvella Therapeutics, Inc. SEC filings · US GAAP · Palvella Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026